The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Encorafenib + binimetinib (Brand name: Braftovi + Mektovi)
- Manufactured by
Array BioPharma, Inc.
FDA-approved indication: June 2018, approved in combination for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
National Library of Medicine Drug Information Portal
Pembrolizumab (Brand name: Keytruda)
- Manufactured by
Merck, Sharp & Dohme Corp
FDA-approved indication: Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
National Library of Medicine Drug Information PortalMedline Plus Health Information
Trametinib (Brand name: Mekinist)
- Manufactured by
GlaxoSmithKline, LLC
FDA-approved indication: Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.
National Library of Medicine Drug Information Portal
Trametinib and dabrafenib combination (Brand name: Mekinist And Tafinlar)
- Manufactured by
Novartis Pharmaceuticals Corporation
FDA-approved indication: April 2018 approved combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.
National Library of Medicine Drug Information Portal
Nivolumab (Brand name: Opdivo)
- Manufactured by
Bristol-Myers Squibb Co
FDA-approved indication: Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. And treatment of patients with melanoma with involvement of lymph nodes or metestatic disease who have undergone complete resection.
National Library of Medicine Drug Information PortalMedline Plus Health Information
Peginterferon Alfa-2b (Brand name: Sylatron)
- Manufactured by
Schering/Merck
FDA-approved indication: Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy
National Library of Medicine Drug Information Portal
Dabrafenib (Brand name: Tafinlar)
- Manufactured by
GlaxoSmithKline, LLC
FDA-approved indication: Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.
National Library of Medicine Drug Information Portal
Technetium Tc99m sulfur colloid injection, lyophilized (Brand name: Technetium Tc99m Sulfur Colloi)
- Manufactured by
Pharmalucence, Inc.
FDA-approved indication: Localization of lymph nodes draining a primary tumor in patients with melanoma when used with a hand-held gamma counter
National Library of Medicine Drug Information Portal